|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 325 7th Street NW, 9th Floor |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 31348-12
|
||||||||
|
6. House ID# 340040000
|
TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Jonathan Heafitz |
Date | 1/20/2022 2:32:53 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to prescription drug coverage and pharmacy benefits
Regulatory and proposed legislative changes to Medicare Part D prescription drug benefits
Access to prescription drugs during the coronavirus pandemic
S.298 / H.R.1829: Pharmacy Benefit Manager Accountability Study Act of 2021
H.R.2410: Medicare and You Handbook Improvement Act
H.R.2484: Lowest Price for Patients Act
H.R.2608: Ensuring Seniors Access to Local Pharmacies Act
H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
H.R.19: Lower Costs, More Cures Act
H.R.2846: Ensuring Access to Lower-Cost Medicines for Seniors Act
H.R.2855: Star Ratings for Biosimilars Act
S.1523: The Drug Price Transparency Act
H.R.3173: Improving Seniors Timely Access to Care Act
S.1909 / H.R.3554: Pharmacy DIR Reform to Reduce Senior Drug Costs Act
H.R.3682: Improving Transparency to Lower Drug Costs Act
S.2164: Lower Costs, More Cures Act of 2021
H.R.4121: To codify a final rule issued by the Secretary of Health and Human Services relating to fraud and abuse and the removal of safe harbor protection for certain drug rebates, and for other purposes
H.R.4158: To amend titles XVIII and XIX of the Social Security Act to eliminate cost sharing with respect to coverage of insulin as a covered part D drug under the Medicare program or as a covered outpatient drug under the Medicaid program
H.R.2815: BIOSIM Act
S.464 / H.R.2163: Safe Step Act
S.1524 / H.R.3029: Health Care PRICE Transparency Act
H.R.4418: SPIKE Act
H.R.5237: A bill to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes.
H.R.5260: Reduced Costs and Continued Cures Act
H.R.3684: The Infrastructure Investment and Jobs Act, Sec.90006, Moratorium on implementation of rule relating to eliminating the anti-kickback statute safe harbor protection for prescription drug rebates
H.R.5376: The Build Back Better Act, Sec. 139301, Prohibiting implementation of rule relating to eliminating the anti-kickback statute safe harbor protection for prescription drug rebates
H.R.5623: The Insulin Cost Reduction Act, To amend title XVIII of the Social Security Act to prohibit price concessions with respect to insulin drugs and exceptions under Part D of Medicare, and for other purposes
42 CFR Part 1001 RIN 0936-AA08: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
JC |
Scott |
|
|
|
Kristin |
Bass |
|
|
|
Jonathan |
Heafitz |
|
|
|
Katherine |
Murphy |
|
|
|
Jocelyn |
Wiles |
|
|
|
Glen |
Chambers |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to prescription drug coverage and pharmacy benefits
Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits
Access to prescription drugs during the coronavirus pandemic
S.298 / H.R.1829: Pharmacy Benefit Manager Accountability Study Act of 2021
S.464 / H.R.2163: Safe Step Act
S.917: Short on Competition Act
H.R.2355: Opioid Prescription Verification Act
H.R.2410: Medicare and You Handbook Improvement Act
H.R.2484: Lowest Price for Patients Act
H.R.2608: Ensuring Seniors Access to Local Pharmacies Act
H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
H.R.19: Lower Costs, More Cures Act
H.R.2843: STOP GAMES Act
H.R.2846: Ensuring Access to Lower-Cost Medicines for Seniors Act
H.R.2853: BLOCKING Act
H.R.2855: Star Ratings for Biosimilars Act
S.1388: Prescription Pricing for the People Act
S.1425 / H.R.2883: Stop STALLING Act
S.1427 / H.R.2869: Increasing Access to Biosimilars Act
S.1428 / H.R.2891: Preserve Access to Affordable Generics and Biosimilars Act
S.1435 / H.R.2873: Affordable Prescriptions for Patients Act of 2021 / Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
S.1462: Simplifying the Generic Drug Application Process Act
S.1463: Modernizing Therapeutic Equivalence Rating Determination Act
S.1523: The Drug Price Transparency Act
S.1524 / H.R.3029: Health Care PRICE Transparency Act
H.R.3173: Improving Seniors Timely Access to Care Act
S.1909 / H.R.3554: Pharmacy DIR Reform to Reduce Senior Drug Costs Act
H.R.3682: Improving Transparency to Lower Drug Costs Act
S.2164: Lower Costs More Cures Act
H.R.4121: To codify a final rule issued by the Secretary of Health and Human Services relating to fraud and abuse and the removal of safe harbor protection for certain drug rebates, and for other purposes
H.R.4158: To amend titles XVIII and XIX of the Social Security Act to eliminate cost sharing with respect to coverage of insulin as a covered part D drug under the Medicare program or as a covered outpatient drug under the Medicaid program
H.R.4502: Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
H.R.4813: Matts Act
S.2814: Vital Medication Affordability Act
S.1132: Ending Pricey Insulin (EPI) Act
H.R.3062: A bill making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for fiscal year ending September 30, 2022
H.R.6000: The CURES 2.0 Act, To continue the acceleration of the discovery, development, and delivery of 21st century cures, and for other purposes
42 CFR Part 1001 RIN 0936-AA08: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
JC |
Scott |
|
|
|
Kristin |
Bass |
|
|
|
Jonathan |
Heafitz |
|
|
|
Katherine |
Murphy |
|
|
|
Jocelyn |
Wiles |
|
|
|
Glen |
Chambers |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks
Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, direct and indirect remuneration (DIR), pharmacy networks, and mail-service pharmacy
Access to prescription drugs during the coronavirus pandemic
S.298 / H.R.1829: Pharmacy Benefit Manager Accountability Study Act of 2021
H.R.2355: Opioid Prescription Verification Act
H.R.2484: Lowest Price for Patients Act
H.R.2608: Ensuring Seniors Access to Local Pharmacies Act
H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
H.R.19: Lower Costs, More Cures Act
H.R.2855: Star Ratings for Biosimilars Act
S.1388: Prescription Pricing for the People Act
S.1463: Modernizing Therapeutic Equivalence Rating Determination Act
S.1523: The Drug Price Transparency Act
S.1524: Health Care PRICE Transparency Act
S.1909 / H.R.3554: Pharmacy DIR Reform to Reduce Senior Drug Costs Act
S.2164: Lower Costs More Cures Act
42 CFR Part 1001 RIN 0936-AA08: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
JC |
Scott |
|
|
|
Kristin |
Bass |
|
|
|
Jonathan |
Heafitz |
|
|
|
Katherine |
Murphy |
|
|
|
Jocelyn |
Wiles |
|
|
|
Glen |
Chambers |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code POS
16. Specific lobbying issues
Issues related to the use of the United States Postal Service (USPS) for prescription drug home delivery
S.1720 / H.R.3076: The Postal Service Reform Act of 2021
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Heafitz |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |